NATCO PHARMA
Back to Balance Sheet
|
NATCO PHARMA Last 5 Year Deferred Tax Assets / Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Deferred Tax Assets / Liabilities | ₹-232 Cr | ₹-50 Cr | ₹-19 Cr | ₹12 Cr | ₹30 Cr |
What is the latest Deferred Tax Assets / Liabilities ratio of NATCO PHARMA ?
| Year | Deferred Tax Assets / Liabilities |
|---|---|
| Mar2026 | ₹-232 Cr |
| Mar2025 | ₹-50 Cr |
| Mar2024 | ₹-19 Cr |
| Mar2023 | ₹12 Cr |
| Mar2022 | ₹30 Cr |
How is Deferred Tax Assets / Liabilities of NATCO PHARMA Trending?
| Years | Deferred Tax Assets / Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹-232 Cr | Negative | |
| Mar2025 | ₹-50 Cr | Negative | |
| Mar2024 | ₹-19 Cr | Negative | |
| Mar2023 | ₹12 Cr | -58.80 | |
| Mar2022 | ₹30 Cr | - | |
Compare Deferred Tax Assets / Liabilities of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹14,798.1 Cr | -1.4% | -8.9% | -3.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹448,316.0 Cr | -1.9% | -3.7% | 18.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹251,737.0 Cr | 2.6% | 11.1% | 56% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹187,594.0 Cr | 0.2% | 1.3% | 38% | Stock Analytics | |
| CIPLA | ₹110,515.0 Cr | -1.5% | -6.4% | -12.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹95,420.6 Cr | -1% | -5.1% | -8.1% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | -1.4% |
-8.9% |
-3.5% |
| SENSEX | -2.4% |
-4.8% |
-7.2% |
You may also like the below Video Courses